Polatuzumab vedotin (Polivy)
- Status:
- Red
- Decision Date:
- June 2020
Comments
RED:
- NICE TA649 - Polatuzumab vedotin with rituximab and bendamustine for refractory diffuse large B-cell lymphoma. (Decision date - October 2020)
- NICE TA874 - Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma. (Decision date - April 2023)
Red Drug Classifications
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again